{"id":40214,"date":"2025-08-27T13:21:26","date_gmt":"2025-08-27T05:21:26","guid":{"rendered":"https:\/\/flcube.com\/?p=40214"},"modified":"2025-08-27T13:21:26","modified_gmt":"2025-08-27T05:21:26","slug":"humanwell-secures-nmpa-approval-for-remimazolam-icu-sedation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40214","title":{"rendered":"Humanwell Secures NMPA Approval for Remimazolam ICU Sedation"},"content":{"rendered":"\n<p>China\u2011based <strong>Humanwell Healthcare (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600079:SHA\">SHA: 600079<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has granted a new therapeutic indication for its ultra\u2011short\u2011acting benzene\u2011sulfonate derivative, <strong>remimazolam<\/strong>. The drug can now be prescribed as a sedative for patients requiring mechanical ventilation in intensive\u2011care units (ICUs).<\/p>\n\n\n\n<p><strong>What Is Remimazolam?<\/strong><\/p>\n\n\n\n<p>Remimazolam is a <strong>GABA<sub>A<\/sub> receptor agonist<\/strong> engineered for rapid onset and offset of action. Co\u2011developed with German company <strong>Paion AG<\/strong>, the drug\u2019s pharmacokinetic profile offers a predictable, short\u2011acting sedative effect that is especially advantageous in critical\u2011care settings where swift titration and recovery are paramount.<\/p>\n\n\n\n<p><strong>New NMPA Indication<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Approved use:<\/strong> Sedation of ICU patients undergoing mechanical ventilation.<\/li>\n\n\n\n<li><strong>Existing approvals (since July\u202f2020):<\/strong><\/li>\n\n\n\n<li>Sedation and anesthesia for procedures without tracheal intubation.<\/li>\n\n\n\n<li>Induction and maintenance of general anesthesia.<\/li>\n<\/ul>\n\n\n\n<p>The latest approval expands remimazolam\u2019s therapeutic reach to a high\u2011risk, high\u2011volume patient population, potentially reducing the need for traditional benzodiazepines and propofol.<\/p>\n\n\n\n<p><strong>Strategic Impact for Humanwell<\/strong><br>Humanwell will now supply remimazolam under the <strong>NMPA\u2019s Category\u202f1 chemical injectable<\/strong> designation, positioning the company as a key player in critical\u2011care drug markets. The partnership with Paion AG also underscores Humanwell\u2019s commitment to global collaboration and technology transfer.<\/p>\n\n\n\n<p><strong>Industry Reactions<\/strong><\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cThis new indication underscores remimazolam\u2019s versatility and our confidence in its safety profile for ICU sedation,\u201d said <strong>Dr. Li Wei<\/strong>, Chief Medical Officer at Humanwell. \u201cWe anticipate rapid adoption in China\u2019s expanding intensive\u2011care sector.\u201d<\/p>\n\n\n\n<p>\u201cThe NMPA\u2019s decision aligns with global trends toward safer, more controllable sedatives in critical care,\u201d noted <strong>Dr. Anna M\u00fcller<\/strong>, Head of Critical Care at a leading German hospital.<\/p>\n<\/blockquote>\n\n\n\n<p><strong>Looking Ahead<\/strong><br>Humanwell plans to launch a national distribution campaign in Q4\u202f2025, targeting hospitals with ICU capacities exceeding 50 beds. The company also aims to explore additional indications in the United States and Europe, leveraging its robust partnership with Paion AG.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40215,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[266,15,1098],"class_list":["post-40214","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-humanwell-healthcare","tag-product-approvals","tag-sha-600079"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Humanwell Secures NMPA Approval for Remimazolam ICU Sedation - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA) has granted a new therapeutic indication for its ultra\u2011short\u2011acting benzene\u2011sulfonate derivative, remimazolam. The drug can now be prescribed as a sedative for patients requiring mechanical ventilation in intensive\u2011care units (ICUs).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40214\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Humanwell Secures NMPA Approval for Remimazolam ICU Sedation\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA) has granted a new therapeutic indication for its ultra\u2011short\u2011acting benzene\u2011sulfonate derivative, remimazolam. The drug can now be prescribed as a sedative for patients requiring mechanical ventilation in intensive\u2011care units (ICUs).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40214\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-27T05:21:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2702.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40214#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40214\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Humanwell Secures NMPA Approval for Remimazolam ICU Sedation\",\"datePublished\":\"2025-08-27T05:21:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40214\"},\"wordCount\":322,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40214#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2702.webp\",\"keywords\":[\"Humanwell Healthcare\",\"Product approvals\",\"SHA: 600079\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40214#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40214\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40214\",\"name\":\"Humanwell Secures NMPA Approval for Remimazolam ICU Sedation - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40214#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40214#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2702.webp\",\"datePublished\":\"2025-08-27T05:21:26+00:00\",\"description\":\"China\u2011based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA) has granted a new therapeutic indication for its ultra\u2011short\u2011acting benzene\u2011sulfonate derivative, remimazolam. The drug can now be prescribed as a sedative for patients requiring mechanical ventilation in intensive\u2011care units (ICUs).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40214#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40214\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40214#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2702.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2702.webp\",\"width\":1080,\"height\":608,\"caption\":\"Humanwell Secures NMPA Approval for Remimazolam ICU Sedation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40214#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Humanwell Secures NMPA Approval for Remimazolam ICU Sedation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Humanwell Secures NMPA Approval for Remimazolam ICU Sedation - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA) has granted a new therapeutic indication for its ultra\u2011short\u2011acting benzene\u2011sulfonate derivative, remimazolam. The drug can now be prescribed as a sedative for patients requiring mechanical ventilation in intensive\u2011care units (ICUs).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40214","og_locale":"en_US","og_type":"article","og_title":"Humanwell Secures NMPA Approval for Remimazolam ICU Sedation","og_description":"China\u2011based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA) has granted a new therapeutic indication for its ultra\u2011short\u2011acting benzene\u2011sulfonate derivative, remimazolam. The drug can now be prescribed as a sedative for patients requiring mechanical ventilation in intensive\u2011care units (ICUs).","og_url":"https:\/\/flcube.com\/?p=40214","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-27T05:21:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2702.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40214#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40214"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Humanwell Secures NMPA Approval for Remimazolam ICU Sedation","datePublished":"2025-08-27T05:21:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40214"},"wordCount":322,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40214#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2702.webp","keywords":["Humanwell Healthcare","Product approvals","SHA: 600079"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40214#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40214","url":"https:\/\/flcube.com\/?p=40214","name":"Humanwell Secures NMPA Approval for Remimazolam ICU Sedation - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40214#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40214#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2702.webp","datePublished":"2025-08-27T05:21:26+00:00","description":"China\u2011based Humanwell Healthcare (Group) Co., Ltd. (SHA: 600079) announced that the National Medical Products Administration (NMPA) has granted a new therapeutic indication for its ultra\u2011short\u2011acting benzene\u2011sulfonate derivative, remimazolam. The drug can now be prescribed as a sedative for patients requiring mechanical ventilation in intensive\u2011care units (ICUs).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40214#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40214"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40214#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2702.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2702.webp","width":1080,"height":608,"caption":"Humanwell Secures NMPA Approval for Remimazolam ICU Sedation"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40214#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Humanwell Secures NMPA Approval for Remimazolam ICU Sedation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2702.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40214"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40214\/revisions"}],"predecessor-version":[{"id":40216,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40214\/revisions\/40216"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40215"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}